Global Health & Pharma's Biotechnology Awards honor pioneers and innovators in this important and ever-evolving area.

The Biotechnology award is evaluated based on the achievements and excellence of the nominees, such as business performance, growth, breakthrough innovations, and customer feedback. To make the final selection, the Global Health & Pharma Voting Panel collects independent information from a variety of publicly available sources.

Genetic testing is becoming increasingly prevalent on an international scale. Be it testing for hereditary diseases or playing a role in devising treatments for genetic illnesses, it holds an array of benefits for people of all different backgrounds. GENETICA US, an American company, has worked to increase both education and safe and accurate testing within the Asian market.  

GENETICA US has maintained a leading role within the genetic testing industry primarily through its utilisation of propriety technologies in AI and molecular biotechnology. 

Moreover, the company is empowered by scientists from some of the world’s most prestigious universities, including University of California San Francisco, Harvard, Stanford, and Cornell. With its headquarters nestled in San Francisco, the company has successfully developed a name for itself within the Southeast Asian market, driving the population towards genetic testing that can subsequently cultivate precision medicine and personalised preventative care. 

Indeed, GENETICA US supplies low-cost genetic testing solutions to the wider population, decoding hundreds of genes and almost a million variants in order to provide its users bespoke reports that result in optimal plans for fitness and diet, child development, and critical illness prevention. From susceptibility to cancers and diabetes, to aiding in weight management, GENETICA US’ is on a mission to improve the health and wellbeing of customers across Asia. In addition, the company’s core technology, upon which it conducts its testing, is built across three key pillars – gene decoding chips, artificial intelligence, and blockchain. These pillars have been internationally recognised by leading organizations, including Thermo Fisher, a world-leading gene testing provider.  

However, the company – despite its innovative nature – has run into one major challenge. 

The lack of understanding surrounding genetic testing. 

Whilst more people are becoming aware of genetic testing, many lack an understanding as to how it actually works. In turn, this can lead to more harm than good with genetic testing, and consequently, it has become imperative for GENETICA US to provide education surrounding the industry. A factor within this misunderstanding is the fact that each laboratory is different – henceforth, the accuracy of the results is dependent upon the standards held within these laboratories. As such, in some cases, customers who have had domestic test reports were asked to order re-testing when sent to the US or other countries because they have not met international standards. 

GENETICA US ensures that it meets these standards, complying with international 

regulations. For example, its U.S. laboratory works in accordance with CLIA standards and HIPPA regulations. In October 2021, a deal between the Vietnam National Innovation Centre (NIC) and GENETICA US came into fruition, with the goal being to develop a genome sequencing centre, the largest of its kind in Southeast Asia. Of course, this laboratory will  also meet international standards, ensuring the most accurate test results, diagnostics, and high personal security levels.  

The Covid-19 pandemic served as a global challenge, casting a negative shadow across numerous industries. In turn, GENETICA US turned its attention towards developing a tool to help diagnose genes that are more susceptible to COVID-19 and the risk of severe 

complications. The company’s research team got to work, discussing the application of artificial intelligence and machine learning in order to find an effective method to combat the virus. As a result, the company’s G-Immunity product was born, which aims to provide information about the risk of viral infections through each patients’ genetic parameters. 

The aforementioned new genome sequencing centre takes priority over the next year as it turns from a blueprint into a full-service laboratory. Operating across Vietnam, the laboratory will meet the increasing demand for genetic testing across the nation, with the added benefit of saving time and reducing costs by up to 30% in comparison to sending samples for analysis in a laboratory in the US. Furthermore, the laboratory will act as the epicentre for major research projects in collaboration with both Vietnam and the world’s leading hospitals, including the Harvard Medical University, the Hue Central Hospital, and the Vietnam National Hospital for Tropical Diseases, among a plethora of others. Indeed, the end goal is to cultivate new discoveries about genetic diseases and to contribute to the development of gene therapy treatments.